Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Between April 2020 and today, the executive board of Kyowa Kiran North America (KKNA) has grown from being predominantly male to a 50/50 gender split.
The duo’s mission is to identify more patients who could benefit from precision medicines by deploying more CDx tests to healthcare providers.
The study of Molnupiravir will assess 1,300 adult participants 18 and over who cohabitate with someone who has tested positive for the coronavirus and is symptomatic.
Today, activists with the AIDS Healthcare Foundation are setting up to protest in front of Moderna’s Cambridge headquarters.
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
Two former executives of JHL Biotech were indicted on charges of orchestrating the theft of trade secrets, wire fraud exceeding $101 million, and money laundering.
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
In the pivotal Phase III trial, Amneal’s investigational Parkinson’s drug, IPX-203, met its primary endpoint, demonstrating superior “Good On” time in patients with motor fluctuations.
The petition was posted on Monday by shareholder rights law firm Labaton Sucharow.
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
FDA
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Toronto saw the biggest growth in technology jobs of any North American city between 2015 and 2020, while Vancouver, British Columbia also made the top five.
The findings are a culmination of decades of genome DNA sequencing by Lyons and her team, which have resulted in a nearly 100% complete assembly of the cat genome.